• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Special Report: Vaccines in Development- Johnson & Johnson vaccine as another frontrunner

byConstance Wu
January 5, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists

The Johnson & Johnson (J&J) Pharmaceutical Research and Development group has focused its COVID-19 vaccine efforts on a single-dose replication-defective human adenovirus 26 vector (Ad26.COV2.S).1,2,3 This vector deliver recombinant SARS-CoV-2 S protein genes to human cells. While no vaccines of this type are commercially available to prevent human disease, the one licensed vaccine is for the prevention of animal rabies. Development has moved into a Phase 2-2a trial supported by $456 million in grants, aiming to recruit up to 30,000 participants. This phase entails the evaluation of the effectiveness and safety of the vaccine, which follows studies on healthy individuals with various dose ranges in Phase 1. Phase 2a, specifically, aims to identify dosing requirements as well as optimal frequency of dosing. Should the study move to Phase 2b, they will directly assess its efficacy in preventing COVID-19.4 J&J, along with Janssen Vaccines & Prevention, published a preprint of clinical trial results assessing the efficacy of AD26.COV2.S in preventing moderate-to-severe COVID-19 in adults.5 A multicenter Phase 1/2a randomized, double-blinded, placebo-controlled study assessed safety, immunogenicity, and reactogenicity of Ad26.COV2.S at a dose level of 5 x 1010 or 1 x 1011 viral particles (vp) per vaccination, in either single dose or two doses 56 days apart in healthy individuals (18-55 years n = 402; >65 years n = 394). Fatigue, headache, myalgia, and pain at injection site were the most frequent adverse events. After a single dose, seroconversion rate in wtVNA (50% inhibitory concentration – IC50) at day 29 among adults 18-55 years reached 92% for both dose levels. Overall, this study found that a single 5 x 1010 vp dose of Ad26.COV2.S may be protective against COVID-19.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

The Scan by 2 Minute Medicine®: Climate-Driven Crises, Serena’s Mental Fitness Revolution, Superhuman Immunity, and Healthcare on Strike

The 2 Minute Medicine Podcast Episode 55

Tags: Ad26.COV2.Sadenovirus vectorCoronavirusSARS-CoV-2vaccinevaccinesvector
Previous Post

Cardiovascular medications may improve outcomes for patients with type 2 myocardial infarction

Next Post

Occult blood in feces is associated with an increased risk of ischemic stroke and myocardial infarction

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
Chronic Disease

The Scan by 2 Minute Medicine®: Climate-Driven Crises, Serena’s Mental Fitness Revolution, Superhuman Immunity, and Healthcare on Strike

May 7, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 55

April 5, 2025
The Scan by 2 Minute Medicine: The Role of Virtual Reality in Pain Management, WHO’S controversial diagnosis on gaming addictions, the TikTok ban and psychology of doom scrolling, and the risk of smart devices replacing annual checkups
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

April 1, 2025
Next Post
Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Occult blood in feces is associated with an increased risk of ischemic stroke and myocardial infarction

#VisualAbstract: Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for maintenance of HIV-1 viral suppression

#VisualAbstract: Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

Being overweight and obese associated with increased incidence of chronic kidney disease

Outcomes associated with discontinuation of RASi in patients with chronic kidney disease

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.